Bio-Gene Technology Ltd. · ASX:BGT
Bio-Gene Technology — H1 FY2024 Earnings Presentation
12 slides from Bio-Gene Technology's earnings presentation, Mar 5, 2024
Slide 1: Developing New Insecticides Derived From Nature to Achieve High Impact - Globally
Developing New Insecticides Derived From Nature to Achieve High Impact - Globally Tim Grogan Managing Director & CEO 5 March 2024 FY24 Half Year Results & Update ASX:BGT www.bio-gene.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation
Slide 3: FY24 Half Year Report: Key milestones achieved
FY24 Half Year Report Key milestones achieved Significance: 1. Review of Bio-Gene’s development pipeline – public health, consumer & crop protection Focus, clear strategy & communications 2. STK – Qcide® Development & License Agreement Accelerate Qcide AI development 3. Flavocide® & Qcide® - US$10 m
Slide 4: Flavocide Active Constituent - Development Update
Flavocide® Active Constituent - Development Update Development Definition Validation Regulatory Launch stage gate status: (PoC) (R&D) development (market) Active constituent approval End use product approval and product commercialization Active constituent dossier submission Product submissions Manu
Slide 5: Flavocide & Qcide Active Constituents - Development Update
Flavocide® & Qcide® Active Constituents - Development Update ➢ Flavocide scale up (India): Approx. 250kg total planned for June 2024 (equivalent to approx. 500 Ha.) ➢ Pre-application Assistance (APVMA - PAA): Filed – an opportunity to obtain technical advice before submitting an application and prov
Slide 6: Commercial Partner: Clarke Mosquito Control Products, Inc.
Commercial Partner: Clarke Mosquito Control Products, Inc. Flavocide®: U.S. Professional Use – public health & residential Segments: 1. Professional public health mosquito market • Insecticide sales value of the Public Health mosquito market in the US: US$100 million p.a. 2. Residential mosquito con
Slide 7: Commercial Partner: Evergreen Garden Care
Commercial Partner: Evergreen Garden Care Flavocide® & Qcide® : Consumer markets, mosquito and ant control Segment 1. Consumer markets, mosquito and ant control (EU, UK, Australia and New Zealand) • Retail sales value est. of approx. US$600m p.a. • EU market for consumer insecticide products is esti
Slide 8: Commercial Partner: STK Bio-Ag Technologies
Commercial Partner: STK Bio-Ag Technologies Qcide®: Crop protection, aquaculture, professional turf & ornamentals Segment 1. Crop protection, aquaculture, professional turf & ornamentals (worldwide non-exclusive) Progression 2021 – Material Transfer Agreement January 2023 – Binding Term Sheet July 2
Slide 9: Bio-Gene's Strategic Priorities
Bio-Gene’s Strategic Priorities Speed Focused Product Commercial Efficient Use particularly the pre-registration Development Validation of Capital manufacturing and safety studies for Flavocide and Qcide active to deploy our resources against a to build on existing commercial to leverage the funding
Slide 10: Developing Biological Products - Critical Success Factors
Developing Biological Products - Critical Success Factors A unique IP portfolio For a strong and defensible position. Products with a Strong Data Package Showing how and why the new products are unique. Strong Partnerships To enable (multiple) market access. Ability to Manufacture Product Cost-effec
Slide 11: Bio-Gene Investment Proposition
Bio-Gene Investment Proposition Key Expectations for CY 2024 & 2025 Flavocide AI & Qcide AI – data for regulatory filing (est. December 2025 for Flavocide) New & expanded partnering (both Flavocide & Qcide) Medium and Long-Term Factors Supporting Sustained Value Creation Strong industry need for new
Slide 12: Bio-Gene Technology Limited
Developing New Insecticides Derived From Nature to Achieve High Impact - Globally Bio-Gene Technology Limited ASX:BGT bgt.info@bio-gene.com.au www.bio-gene.com.au Registered Office Level 6 400 Collins Street Melbourne, Victoria, 3000 AUSTRALIA 12
Bio-Gene Technology — H1 FY2024 Earnings Presentation on 6ix